Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09GXF
|
|||
| Former ID |
DIB014416
|
|||
| Drug Name |
RB-105
|
|||
| Synonyms |
S-21402; S-21402-1; N-[2(S)-(Mercaptomethyl)-3(R)-phenylbutyl]-L-alanine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hypertension [ICD-11: BA00-BA04; ICD-9: 401] | Investigative | [1], [2], [3] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C14H19NO3S
|
|||
| Canonical SMILES |
CC(C1=CC=CC=C1)C(CS)C(=O)NC(C)C(=O)O
|
|||
| InChI |
1S/C14H19NO3S/c1-9(11-6-4-3-5-7-11)12(8-19)13(16)15-10(2)14(17)18/h3-7,9-10,12,19H,8H2,1-2H3,(H,15,16)(H,17,18)/t9-,10-,12-/m0/s1
|
|||
| InChIKey |
ABBSOQIXYPZCKO-NHCYSSNCSA-N
|
|||
| CAS Number |
CAS 155895-89-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Angiotensin-converting enzyme (ACE) | Target Info | Modulator | [1], [2], [3] |
| Neutral endopeptidase (MME) | Target Info | Modulator | [1], [2], [3] | |
| KEGG Pathway | Renin-angiotensin system | |||
| Hematopoietic cell lineage | ||||
| Protein digestion and absorption | ||||
| Alzheimer's disease | ||||
| Chagas disease (American trypanosomiasis) | ||||
| Hypertrophic cardiomyopathy (HCM) | ||||
| NetPath Pathway | EGFR1 Signaling Pathway | |||
| TGF_beta_Receptor Signaling Pathway | ||||
| Pathwhiz Pathway | Angiotensin Metabolism | |||
| Reactome | Metabolism of Angiotensinogen to Angiotensins | |||
| WikiPathways | Metabolism of Angiotensinogen to Angiotensins | |||
| Primary Focal Segmental Glomerulosclerosis FSGS | ||||
| Alzheimers Disease | ||||
| ACE Inhibitor Pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Reversal of cardiac hypertrophy and fibrosis by S21402, a dual inhibitor of neutral endopeptidase and angiotensin converting enzyme in SHRs. J Hypertens. 2000 Jun;18(6):749-55. | |||
| REF 2 | Renal and vascular effects of S21402, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase, in healthy subjects with hypovol... Clin Pharmacol Ther. 2002 Jun;71(6):468-78. | |||
| REF 3 | Beneficial renal and cardiac effects of vasopeptidase inhibition with S21402 in heart failure. Hypertension. 2000 Dec;36(6):1105-11. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.